Randomized trial · people
Exenatide: lower intracranial pressure in IIH over 12 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a small early trial, exenatide lowered skull pressure in women with IIH within hours, and the drop held through 12 weeks.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 16
- Published
- 2023
- Journal
- Brain
What they tested
The team tested whether exenatide lowers pressure inside the skull in women with idiopathic intracranial hypertension (IIH, raised skull pressure with no known cause).
How the study was done
A randomized, placebo-controlled, double-blind trial in 16 adult women with active IIH, defined as pressure above 25 cmCSF (a unit of skull pressure) plus papilledema (swelling at the back of the eye), given exenatide or placebo (a dummy shot) under the skin. Implanted sensors tracked skull pressure over time, and 15 women finished the 12-week study.

What they found
At the start, the women averaged 28 ± 9 years of age, a body mass index of 38.1 ± 6.2 kg/m2 and a skull pressure of 30.6 ± 5.1 cmCSF. Exenatide lowered skull pressure by -5.7 ± 2.9 cmCSF at 2.5 hours (P = 0.048), -6.4 ± 2.9 cmCSF at 24 hours (P = 0.030) and -5.6 ± 3.0 cmCSF at 12 weeks (P = 0.058). The trial set its threshold for a significant result at a P value under 0.1, chosen before it began. No serious safety signals were seen.
What it doesn’t show
This was a very small trial of 16 women, 15 of whom finished, and it lasted 12 weeks. It included only adult women with active IIH, and the team saw the results as a reason to move on to a phase 3 trial.
The paper
Mitchell et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023.
The compound
More studies on Exenatide
- Exenatide: no cognitive benefit in mild cognitive impairmentRandomized trial · people · 2024
- Exenatide did not cut heavy drinking days in alcohol use disorderRandomized trial · people · 2022
- Exenatide: 29.2% spontaneous pregnancy vs 14.7% on metformin in PCOSRandomized trial · people · 2022
- Exenatide plus dapagliflozin: UACR fell 39.6% vs 11.0% on placeboRandomized trial · people · 2021
- Exenatide, alone or with dapagliflozin, improved blood sugar in PCOSRandomized trial · people · 2021
- Exenatide ER: 0.9% HbA1c drop vs 1.5% with semaglutide in SUSTAIN 3Randomized trial · people · 2018
- Every study on Exenatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.